Lorenza Rimassa

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng et al. · New England Journal of Medicine · 2018 · 2.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Arndt Vogel, John Bridgewater, Julien Edeline et al. · Annals of Oncology · 2022 · 633 citations · Full text

Medicine, Oncology, Surgery +14

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath et al. · The Lancet Oncology · 2012 · 550 citations

Medicine, Oncology, Pharmacology +9